BioPharma Resources

Investigational drug · Phase 3

INS1009

Also called: Treprostinil Palmitil

Not approved by FDA. In 7 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Interstitial Lung Disease, Pulmonary Hypertension, Pulmonary Arterial Hypertension.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

7

5 still active

All registered trials

12

Any phase or sponsor naming "INS1009"

First trial start

2022

Aug 24, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "INS1009", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Interstitial Lung Disease
  • Pulmonary Hypertension
  • Pulmonary Arterial Hypertension
  • Progressive Pulmonary Fibrosis

Approved drugs for the same conditions: High blood pressure (hypertension) · Pulmonary arterial hypertension · Cardiovascular and metabolic · Respiratory

Largest trials

Live from ClinicalTrials.gov: studies naming "INS1009" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 13 on PubMed

Also in development for Interstitial Lung Disease

  • MK-7240PRA023, TulisokibartPhase 310 trials

    Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease

  • Inhaled TreprostinilLIQ861 Inhaled Treprostinil, Inhaled prostacyclinPhase 35 trials

    United Therapeutics · Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

  • ATYR1923KRP-R120, EfzofitimodPhase 32 trials

    aTyr Pharma, Inc. · Interstitial Lung Disease, Pulmonary Sarcoidosis

  • MosliciguatPhase 32 trials

    Pulmovant, Inc. · Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.